First, let's get one thing out of the way. Investing in small-cap stocks can be very risky. These companies aren't worth much for a reason; most investors don't see them as attractive options. And while the majority isn't always right, it is still worth it to at least consider widespread opinions.

On the other hand, many established corporations were once small-cap stocks. So clearly, some companies in this category are worth investing in. Let's consider two small-cap stocks that carry above-average risk but that could soar as early as next year if things work out: Bluebird Bio (NASDAQ: BLUE) and Krystal Biotech (NASDAQ: KRYS).

Bluebird Bio is a biotech that seeks to develop gene-editing treatments for rare illnesses. Some of the company's efforts came to fruition this year as it finally earned U.S. approval for two therapies. The first is Zynteglo, a treatment for a blood-related disorder called transfusion-dependent beta-thalassemia.

Continue reading

Source Fool.com